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Peritoneal dialysis (PD) has been a successful form of As a result of the growing awareness of the potential
chronic renal replacement therapy for more than twenty effects of glucose-based solutions on membrane physiol-
years. In spite of the successes of this therapy, there is ogy, there has been an increased emphasis on the devel-
a growing awareness that the high glucose content of PD opment of second-generation PD solutions that reduce
solutions may ultimately compromise membrane perfor- or eliminate glucose exposure and are more biocompati-
mance over time, a realization that underlies the search ble with membrane biological and metabolic processes
for, and production of, glucose-free solutions. Icodextrin, [30–34].
one of the second-generation PD solutions, was devel- The biocompatibility of a PD solution can be defined
oped as an alternative to glucose-based solutions to pro- as the ability of a solution formulation to permit long-
vide a sustained level of ultrafiltration through the use term dialysis without any clinically significant changes
of a glucose polymer as the osmotic agent, and is cur- in the functional characteristics of the peritoneum and,
rently used by more than 9000 patients worldwide. While as such, is of paramount importance not only in main-
icodextrin has now proven itself to be clinically useful taining the health of the membrane, but also in permit-
in the fluid management of PD patients, there are indica- ting PD to be a successful long-term therapy. The poten-
tions that it also may demonstrate improved biocompati- tial role of PD solution biocompatible factors in clinical
bility when compared to the traditional solutions. This outcomes is illustrated in Figure 1. Solution components
review evaluates the biocompatibility of icodextrin ver- can affect leukocyte, mesothelial cell, endothelial cell, and
sus glucose-based solutions, and shows how this new fibroblast function, resulting in alterations in cytokine,
solution may significantly contribute to an overall thera- chemokine, and growth factor networks, up-regulation
peutic strategy for improving PD. of pro-inflammatory and profibrotic pathways, impaired
peritoneal host defense, and the induction of carbonyl
and oxidative stress. Such perturbations of normal physi-BIOCOMPATIBILITY
ology have been proposed as causative factors contribut-
The peritoneal membrane is a complex tissue that ing to changes in peritoneal structure, such as peritoneal
plays a pivotal role in peritoneal cavity homeostasis [1]. fibrosis, sclerosis and vasculopathy, and changes in peri-
The cellular components of the membrane are active toneal function, including increased solute permeability
in host defense [2–5], maintain a balance of peritoneal and ultrafiltration (UF) failure.
coagulant and fibrinolytic activity [6–9], contribute to The characteristics of conventional glucose-based dial-
membrane repair and remodeling of the extracellular ysis solutions that have been reported to affect the bio-
matrix [10, 11], and regulate cytokine and chemokine compatibility of the formulation include the pH/buffer
production (Table 1) (abstract; Jo¨rres et al, Nephrol Dial system, the osmolarity, the glucose concentration, and
Transplant 8:1023, 1993) [12–15]. The membrane itself the glucose degradation product (GDP) profile of that
functions as a semipermeable barrier regulating the se- solution. Icodextrin is virtually identical to glucose-based
lective transport of water and solutes between the sys- PD solutions in its formulation except for the replace-
temic circulation and the peritoneal cavity during PD. ment of glucose with icodextrin as the osmotic agent
It is becoming increasingly apparent that, in spite of the (Table 2). Icodextrin is a high molecular weight glucose
success of PD as a renal replacement therapy, chronic polymer fraction of hydrolyzed corn starch. Briefly, it is
exposure to glucose-based solutions may compromise a mixture of d-glucopyranose polymers of different chain
the biological function of the peritoneal membrane [28, 29]. lengths, between 4 and 250 units, linked by -(1-4) and
-(1-6) glucosidic bonds, exhibiting a mean molecular
weight of 16,200 Daltons (D). The chemical propertiesKey words: renal replacement therapy, CAPD, APD, dialysate, mem-
brane permeability, ultrafiltration, peritoneal cavity homeostasis. of icodextrin produce a colloidal, rather than crystalline
osmotic pressure that, in effect, maintains sustained ul- 2002 by the International Society of Nephrology
S-34
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Table 1. Molecules produced by peritoneal mesothelial cells
Activity Molecule Category References
Host defense IL-1, IL-1, IL-6, IL-8, IL-10, IL-15 Pro- & anti-inflammatory cytokines [12–16]
MCP-1, RANTES Chemokines [12, 16]
ICAM-1, VCAM-1 Adhesion molecules [17]
PGE2, PGI2 Prostaglandins [18]
Catalase, SOD, glutathione peroxidase Anti-oxidant enzymes [19]
Coagulant and fibrinolytic tPA, uPA, PAI-1, PAI-2 Fibrinolytic enzymes, pro-coagulant [6–9]
activity enzymes
Membrane repair and TGF-, fibronectin, laminin, collagens type I, III, IV Growth factors, extracellular matrix [20–23]
remodeling components
MMP-2, MMP-3, MMP-9 Matrix metalloproteinases [10]
TIMP-I, TIMP-II, TIMP-III Tissue inhibitors of MMPs [10]
Hyaluronin, HA synthase, decorin, biglycan Proteoglycans [24, 25]
Water, glucose transport AQPs Aquaporins [26]
GLUT Glucose transporters [27]
Abbreviations are: IL, interleukin; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated upon activation, normal T cell expressed and secreted;
ICAM, intercellular adhesion molecule; VCAM, vascular cellular adhesion molecule; PGE2 and PGI2, prostaglandin E2 and I2; SOD, superoxide dismutase; tPA
and uPA, tissue-type and urokinase-type plasminogen activator; TGF-, transforming growth factor-; MMP, matrix metalloproteinase; TMP, tissue inhibitor of
metalloproteinase; HA, hyaluronin; AQP, aquaporin; GLUT, glucose transporters.




Glucose g/L 13.6, 22.5 or 38.6 —
Glucose polymer g/L — 75
Sodium mEq/L 132 132
Chloride mEq/L 96 96
Calcium mEq/L 3.5 3.5
Magnesium mEq/L 0.5 0.5
Lactate mEq/L 40 40
Osmolality mOsm/kg 358, 401, or 511 282
pH 5.2 5.2
reviewed. The role of pH and buffer system will not be
a focus of this review because the icodextrin-based solu-
Fig. 1. Potential role of biocompatibility in clinical outcomes. Chronic
tion formulation in this respect is similar to conventionalexposure to bioincompatible PD solutions can result in perturbations
in normal cellular physiology. These changes in membrane structure glucose-based solutions.
and function can ultimately result in declining peritoneal transport and
ultrafiltration, and worsening clinical outcomes.
GLUCOTOXICITY
For the past twenty years, glucose has been used suc-
cessfully as the osmotic agent in PD solutions. Yet, in or-trafiltration for the long dwell in both continuous ambu-
der to generate effective ultrafiltration during CAPD,latory peritoneal dialysis (CAPD) and automated perito-
the glucose concentration (75 to 214 mmol/L) must typi-neal dialysis (APD) [35, 36]. A complete description of
cally be 15 to 40 times physiological levels (within thethe chemical characteristics of icodextrin can be found
range of 1500 to 4250 mg/dL). There is growing concernin Alsop [37], and elsewhere in this Supplement issue of
that the continuing and long-term chronic exposure toKidney International.
high levels of glucose has serious adverse metabolic ef-This review discusses the biocompatibility profile of
fects on peritoneal tissues. It has been noted that tissuesicodextrin PD solution in terms of its potential to avoid
from long-term PD patients bear pathologic alterationsglucose and hyperosmolarity-mediated cytotoxicity, and
strikingly similar to diabetiform vascular disease, with aGDP- and advanced glycation end product (AGE)-medi-
thickening of the basement membrane, vascular altera-ated cellular alterations. Secondly, the contribution of the
tions, and AGE deposition [38–41]. An overview of peri-PD solution per se to peritoneal carbonyl stress versus
toneal glucotoxicity—mechanisms by which glucose di-the contribution of the uremic milieu will be described,
and the potential benefit of icodextrin in this context rectly or indirectly affects structural and functional alter-
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Fig. 2. Mechanisms of peritoneal glucotoxi-
city. Abbreviations are: TGF-1, transforming
growth factor-1; VEGF, vascular endothelial
growth factor; AGE, advanced glycation end
products. (Reprinted from reference [33] with
permission of Peritoneal Dialysis International.)
ations in the membrane—is shown in Figure 2 and is The glucose-mediated up-regulation of molecular
pathways in mesothelial cells most likely has a significantsummarized below.
High glucose-mediated changes in mesothelial cell role in peritoneal membrane dysfunction [26, 33, 48–51].
The direct effects on the polyol pathway and specific genesgene expression noted in cell culture assays may be caus-
ally related to changes in peritoneal membrane structure such as protein kinase C (PKC), TGF-, VEGF, and
MCP-1 are thought to facilitate the development of peri-and function. High glucose is able to up-regulate trans-
forming growth factor- (TGF-) [42, 43] and fibronectin toneal fibrosis and extracellular matrix (ECM) expansion
and increased angiogenesis, which are strongly suspected[44, 45] mRNA and protein expression in mesothelial
cells. In addition, the subsequent activation of vascular to result in altered ultrafiltration over time. Exposure of
the membrane components to high glucose also can haveendothelial growth factor (VEGF) by TGF- in human
[abstract; Witowski et al, Perit Dial Int 21(Suppl 1):S21, an indirect effect on membrane function, through AGE
formation leading to subsequent alterations in the meso-2001] and rat [46] peritoneal mesothelial cells suggests
a relationship between high glucose exposure, peritoneal thelial, interstitial, and endothelial layers of the mem-
brane (detailed later in this article) [52–54].fibrosis, and changes in transport seen in long-term pa-
tients and in a rat model of TGF- overexpression [46]. One of the anticipated benefits of icodextrin is being
High glucose, TGF-, and hyperosmolarity all may con- able to reduce the level of peritoneal membrane glucose
tribute to damaged intercellular junctions in human peri- exposure. This has the potential to significantly minimize
toneal mesothelial cells (HPMCs), suggesting that high many of the glucose-related cytotoxicities, and therefore
glucose dialysate could induce peritoneal hyperpermea- better preserve normal membrane physiology as it relates
bility and a progressive reduction in dialysis efficacy [47]. to the ability of the membrane to function effectively as
It also has been noted that high glucose up-regulates mono- a dialysis membrane.
cyte chemotactic protein-1 (MCP-1) in HPMCs [16]. As
MCP-1 is a chemoattractant for peritoneal macrophages,
HYPEROSMOLAR STRESSmajor participants in peritoneal fibrosis through the syn-
Glucose-based PD solutions are significantly hyperos-thesis of various cytokines and growth factors, it may
molar relative to serum, while icodextrin at 282 mOsmprovide an alternative route to mediate peritoneal fibro-
is iso-osmolar to normal plasma (Table 2). There are nu-sis. And finally, the effects of high glucose on the genera-
merous in vitro studies that detail how peripheral bloodtion of reactive oxygen species (ROS) in HPMCs have
and peritoneal leukocytes and mesothelial cells are ad-been reviewed [48]. ROS serve as signaling molecules
versely affected by exposure to hyperosmolar solutionsfor protein kinases and transcription factors including
(Table 3). In an early study designed to evaluate thenuclear factor-B (NF-B) and, as such, their up-regula-
biocompatibility of iso-osmolar solutions, de Fijter et altion by high glucose may be important in altering pat-
demonstrated improved phagocytic and respiratory burstterns of gene activation (for example, TGF- and fibro-
nectin) in peritoneal tissues. activity in both polymorphonuclear cells and monocytes
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Table 3. Effects of glucose and icodextrin on different cell types
Glucose Icodextrin References
Mesothelial cells Increased PGE2 expressiona No change in PGE2 expressiona [18]
(primary culture) tPA inductiona No change in tPAa [55]
Mesothelial cells Abnormal morphologyc Normal morphologyb [56]
(from effluent) Reduced proliferationc Improved proliferationb [56]
Polymorphonuclear cells Cytotoxicitya No significant cytotoxicitya [57]
(peripheral blood) Reduced phagocytosisa Increased phagocytosisb [58]
Reduced respiratory bursta Increased respiratory burstb [58, 59]
Reduced superoxide productiona Increased superoxide productionb [59]
Reduced leukotriene B4 synthesisa Increased LTB4 synthesisb [60]
Monocytes Reduced phagocytosisa Increased phagocytosisb [58]
(peripheral blood) Reduced respiratory bursta Increased respiratory burstb [58, 59]
Reduced superoxide productiona Increased superoxide productionb [59]
Macrophages Reduced phagocytosisc Increased phagocytosisb [58]
(from effluent) Reduced respiratory burstc Increased respiratory burstb [58]
a Compared to control
b Compared to glucose solution
c Compared to icodextrin solution
Fig. 4. Icodextrin does not affect tissue plasminogen antigen (tPA)Fig. 3. Icodextrin does not affect prostaglandin E2 (PGE2) synthesis
synthesis in cultured human peritoneal mesothelial cells. HPMCs werein cultured human peritoneal mesothelial cells (HPMCs). HPMCs were
incubated for 24 hours in culture medium containing 2% human serumincubated for 24 hours in culture medium containing 2% human serum
and d-glucose, mannitol, or l-glucose (each at 90 mmol/L) or icodextrinand d-glucose, mannitol, or l-glucose (each at 90 mmol/L) or icodextrin
(7.5%). Control cells were incubated in medium plus serum. Levels of(7.5%). Control cells were incubated in medium plus serum. PGE2 in
tPA antigen in culture medium were measured by ELISA. Values areculture medium was measured by ELISA. Values are mean  SEM,
mean SEM, N 5. *P 0.05 compared to control. Figure is adaptedN  7. *P  0.05 compared to control. Figure is adapted from Sitter
from Sitter et al [55] with permission from Thrombosis and Haemostasis.et al [18] with permission from the American Society of Nephrology.
also been demonstrated that tissue-type plasminogen ac-exposed to icodextrin versus glucose-based solutions
tivator (tPA) induction in HPMCs was dependent mainly[58], implying improved biocompatibility of icodextrin.
on hyperosmolarity and mediated through PKC while,When the effect of hyperosmolarity was studied in meso-
in contrast, icodextrin did not affect tPA production,thelial cells, Sitter et al showed that the synthesis of
and therefore may not play as direct a role in mediatingprostaglandin E2 (PGE2) in cultured mesothelial cells
the fibrinolytic balance in the peritoneal cavity (Fig. 4)exposed to icodextrin (7.5% in culture medium) was
[55]. Hyperosmolar glucose exposure was shown to en-unchanged relative to control, but was significantly in-
hance the expression of aquaporin-1 (AQP-1) mRNAcreased in cells exposed to 90 mmol/L d-glucose (Fig. 3)
and protein in cultured human peritoneal mesothelial[18]. Increased PGE2 is associated with protein loss in the
cells [26] and increase the abundance of AQP-1 proteinperitoneum [61] and with macrophage cytokine down-
in the plasma membrane of cultured rat peritoneal meso-regulation [62]; normalization of PGE2 levels through the
thelial cells [51]. Aquaporins are expressed by a numberuse of iso-osmolar icodextrin therefore may contribute to
improved membrane function and host defense. It has of cell types including peritoneal endothelial and meso-
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thelial cells, and are thought to be equivalent to the
ultrasmall water pores of the peritoneum specific for
water transport. While they may play an important role
in dialysis adequacy and fluid balance in peritoneal dial-
ysis, their role, if any, in ultrafiltration failure is still un-
known [63]. Finally, Ha et al reported that icodextrin and
glucose-based solutions had similar effects in mesothelial
cells on cell proliferation, DNA damage and cytotoxicity
Fig. 5. Icodextrin preserves mesothelial cell viability and morphology.[48]. These authors found that HPMC proliferation ap- HPMCs recovered from dialysis effluents after an overnight dwell using
peared to be more affected by high osmolarity than were either icodextrin- or glucose-based solutions were evaluated for cell
viability and morphology. HPMCs from icodextrin effluent show acytotoxicity or DNA damage, which were more sensitive
greater percentage of total cells with a normal morphology than thoseto low pH and/or high GDP levels. recovered from glucose effluent (A ) and fewer cells with atypical mor-
There have been numerous studies evaluating the im- phology after culture in vitro (B ). Data are derived from Bajo et al
(abstract; Nephrol Dial Transplant 14:A249, 1999).pact of PD solutions on cellular functions that do not
specifically identify hyperosmolarity as the causative fac-
tor. Thomas et al observed enhanced respiratory burst
activity as well as increased superoxide anion generation change in icodextrin had a more normal morphology
in polymorphonuclear cells and monocytes with icodex- and greater proliferation capacity than cells from the
trin-containing solutions [59]. In their study, the bacteri- same patients collected from an overnight 2.27% glucose
cidal activity of polymorphonuclear cells was improved (2.5% dextrose) exchange (Fig. 5) [56], suggesting im-
in icodextrin compared to 1.5% glucose, with no differ- proved biocompatibility with icodextrin. In contrast, in
ence in monocytes. There was no difference in phagocy- a mouse model Gotloib et al observed decreased perito-
tosis in either cell type. While the authors attributed the neal mesothelial cell density and viability after intraperi-
differences observed to low osmotic stress with icodex- toneal exposure to both glucose- and icodextrin-based
trin, they were not able to rule out the possible contribu- solutions [65]. The authors attributed these cytotoxic
tions of glucose toxicity or GDP toxicity in the glucose effects to glucose, GDP, and AGE-mediated oxidative
solutions tested. Overall, these studies suggest an im- stress, but as those factors are absent or very low in
proved biocompatibility profile for icodextrin. In a study icodextrin-based solutions, the basis of their conclusions
conducted by Jo¨rres et al, there was no difference in may be unfounded.
cytokine release and mRNA synthesis in polymorphonu- Finally, in a prospective clinical study designed to ex-
clear cells exposed to icodextrin and glucose-based PD amine the outcome of long-term exposure to icodextrin,
solutions [57]. However, these authors found no signifi- Posthuma et al evaluated peritoneal membrane trans-
cant cytotoxicity of icodextrin-based solutions, while port kinetics, membrane markers [66] and parameters of
both low and high glucose PD solutions were significantly host defense [67] in continuous cyclic peritoneal dialysis
cytotoxic compared to the control medium. Liberek et (CCPD) patients using either icodextrin or a glucose-
al reported mixed results with higher toxicity in polymor- based solution for the daytime exchange. The investiga-
phonuclear cells, no change in phagocytosis and respira- tors found no difference in their patient populations over
tory burst, and improved leukotriene B4 synthesis in ico- the course of two years for several indicators of host
dextrin versus high glucose PD solution [60]. Plum et al defense (phagocytic cell number, percentage, oxidative
observed reduced cytokine release in monocytes exposed response, and cytokine production), but did see an im-
to the icodextrin solution prepared in their laboratory provement in phagocytosis of S. epidermidis and E. coli
[64], but their results must be interpreted with caution as with icodextrin [67]. Peritoneal markers CA125, interleu-
the polymer studied was purchased from a chemical sup- kin-8, and procollagen propeptides were stable over time,
ply company and therefore was not representative of the and membrane transport of low molecular weight solutes
glucose polymer used in icodextrin-based PD solution. did not change over the course of the study [66].
While cell culture studies are useful in elucidating
mechanisms of PD solution-mediated cytotoxicity, they
GLUCOSE DEGRADATION PRODUCTSare equivocal at best in establishing superiority of icodex-
trin versus glucose. Ex vivo and in vivo studies are more One aspect of glucose-based solution bioincompatibil-
ity is attributed to the presence of GDPs. These low mo-likely to predict the clinical relevance of biocompatibil-
ity. In an ex vivo study, peritoneal macrophages isolated lecular weight compounds are generated primarily from
the breakdown of glucose during the terminal heat steril-from PD patients’ icodextrin effluents exhibited signifi-
cantly enhanced phagocytic capacity and chemilumines- ization process, and include acetaldehyde, formalde-
hyde, 2-furaldehyde, 3-deoxyglucosone (3-DG), glyoxal,cence response compared to cells from glucose effluents
[58]. Mesothelial cells collected from an overnight ex- methyglyoxal, 5-hydroxymethyl-furfural and probably
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Fig. 6. Formation and biological effects of
advanced glycation end products (AGEs) and
advanced lipoxidation end products (ALEs).
Reactive carbonyl compounds (RCOs) are de-
rived in uremia from the glyoxidation of car-
bohydrates, and are present among the glu-
cose degradation products found in standard
PD solutions. RCOs react with proteins to form
Schiff bases via glycation and Amadori adducts
via rearrangements. These early nonenzymatic
events occur within days and are reversible.
Over a period of weeks, the irreversible pro-
cess of advanced glycation occurs via further
rearrangements and cross-linking, resulting in
the formation of AGEs. AGEs, and to a lesser
extent the Schiff base and Amadori adducts,
may contribute to the biological effects of gly-
cation. RCOs derived from lipid peroxidation
react with proteins to form advanced lipoxida-
tion endproducts (ALEs), which share the bio-
logical activities of AGEs. R  protein.
Table 5. Direct comparison of glucose degradation productTable 4. Range of concentrations of glucose degradation products
measured in glucose- or icodextrin-based PD solutions concentrations in icodextrin- and glucose-based dialysis solutions
Compound GlucoseConcentration lmol/L
lmol/L (1.36 %) Icodextrin P value
Glucose-based Icodextrin-based
Compound Formula solutions solution References Glyoxal 6.20.5 2.61.2 0.01
Methylglyoxal 7.80.6 1.90.5 0.001
Acetaldehyde C2H4O 120–420 35 [79, 80] 3-DG 47.24.3 4.10.7 0.001
3-DG C6H10O5 47–118 4.1 [75, 78] Total RCOs 64.78.7 26.44.5 0.01
Formaldehyde CH2O 4.6–15 ND [70, 72]
Data are taken from [71]. Data are duplicate determinations from three inde-2-Furaldehyde C5H4O2 0.05–2 ND [80]
pendent batches expressed as mean  SD. Statistics by the Student t test orGlyoxal C2H2O2 3.0–14 2.6 [80]
ANOVA; P  0.05 is considered statistically significant. RCOs are reactive5-HMF C6H6O3 2.2–30 ND [70, 72] carbonyl compounds.Methylglyoxal C3H4O3 2.0–22.7 1.9 [70, 78, 80]
Glucose-based solutions were commercially available, heat-sterilized solutions
containing 1.36% glucose (1.5% dextrose). Icodextrin-based solution was commer-
cially manufactured, heat-sterilized solution containing 7.5% icodextrin. ND is not
determined. impair viability, combinations of GDPs as found in PD
solutions were cytotoxic, and their effects would most
likely be cumulative over time versus acute or short-term
exposure [73, 81]. In a study on cell viability, icodextrinadditional as yet unidentified compounds [68–71]. GDPs
supported improved proliferation of murine fibroblastsare thought to exert their effects via two mechanisms:
compared to a high-glucose standard PD solution (botheither by direct cytotoxicity (for example, inhibition of
solutions were heat-sterilized and adjusted to neutralcell proliferation), as noted in vitro with formaldehyde,
pH) [79], the difference being attributed to the loweracetaldehyde, and methylglyoxal [72, 73], or indirectly by
levels of GDPs in icodextrin versus the glucose-basedaccelerating the process of AGE formation as seen with
solution.reactive carbonyl compounds (RCOs) such as glyoxal,
methylglyoxal, and 3-DG (Fig. 6 and next section) [74–77].
Icodextrin-based solutions, by virtue of the replacement
PERITONEAL AGE FORMATION ANDof glucose with glucose polymer, have extremely low
CARBONYL STRESSlevels of individual GDPs and total RCOs (Tables 4 and
It has been proposed that the peritoneal cavity of PD5) [54, 78, 79].
patients is in a state of severe overload of carbonyl stressWitowski et al used primary cultures of human meso-
compounds derived not only from glucose-based dialysisthelial cells to confirm the cytotoxic potential of GDPs
solutions (GDPs), but also from the uremic circulation[73, 81], previously explored in transformed fibroblast
[83]. Reactive carbonyl compounds, or RCOs, are gener-cell lines and in peripheral and peritoneal leukocytes
ated in uremic plasma from both carbohydrates and lip-[68, 82]. They concluded that GDPs (acetaldehyde, form-
ids by oxidative and non-oxidative processes. Glucosealdehyde, 2-furaldehyde, glyoxal, 5-hydroxymethyl-fur-
and reactive carbonyl compounds (GDPs) from dialysisfural, or methylglyoxal) pose a significant cytotoxic po-
tential toward HPMCs. While individual GDPs did not solutions, together with uremic derived RCOs, can react
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with proteins to form AGEs and advanced lipoxidation
end products (ALEs; Fig. 6).
Advanced glycation end products and ALEs have
been implicated in a variety of activities that may com-
promise normal membrane function, including protein
and extracellular matrix cross-linking, inflammation, che-
motaxis [84], angiogenesis [85], vascular smooth muscle
cell proliferation [86], and increased nitric oxide (NO)
production [87]. In experiments related to diabetic reti-
nopathy, pathophysiologically relevant levels of AGEs
induced VEGF mRNA and protein expression in retinal
pigment epithelial cells and in bovine vascular smooth Fig. 7. AGE deposition is reduced in icodextrin- versus glucose-treated
diabetic rats. AGE accumulation in the peritoneal membrane of normalmuscle cells in a dose and time dependent fashion [85],
and streptozotocin-induced diabetic rats was measured after 12 weekssuggesting a link between hyperglycemia, AGE forma-
exposure to various dialysis solutions [2.27% glucose (2.5% dextrose)
tion, and VEGF. These events may serve as a model for and 3.86% glucose (4.25% dextrose) or 7.5% icodextrin]. AGE deposi-
tion was most severe in the group exposed only to glucose-based fluidglucose-mediated modifications that affect both perito-
(P  0.016 vs. control diabetics), while deposition in the icodextrinneal membrane structure (such as fibrosis) and function
group was significantly less than the glucose group (P  0.05), and not
(such as increased effective peritoneal surface area), which significantly different from the control diabetics. Data reprinted from
Lee et al [96] with permission from the Society of Peritoneal Dialysis.in turn can lead to increased permeability for glucose
and small solutes, and eventually result in ultrafiltration
failure [88]. AGEs and ALEs have been localized to the
peritoneal membrane of normoglycemic uremic patients
to the AGE receptor (RAGE) in human peritoneal mes-prior to the initiation of PD, a finding that supports the
angial cells (HPMCs) resulted in enhanced vascular cel-contribution of both uremia and increased oxidative
lular adhesion molecule (VCAM-1) expression and leu-stress to AGE formation and membrane alterations [54],
kocyte adhesion [91]. This suggests a mechanism byand suggests that this process is at least partially indepen-
which AGEs contribute to inflammatory processes indent of glucose.
the peritoneal cavity. There is evidence from severalA direct correlation between duration of PD and peri-
studies for a decreased rate of formation of glycated andtoneal tissue AGE content has been described, sug-
AGE-modified protein in vitro with icodextrin- versusgesting that the increased AGE/ALE staining in long-
glucose-based PD solutions [92–95]. Amore et al haveterm patients was potentially due to the glucose-medi-
found apoptotic indices and inducible nitric oxide syn-ated mass transfer of RCOs across the peritoneal mem-
thase (iNOS) activity in HPMCs exposed to icodextrinbrane with subsequent deposition in peritoneal tissues,
equivalent to control basal levels as opposed to cellsand that AGE-induced vascular changes in the mem-
exposed to glucose-based solutions, attributing the im-brane were directly related to increased membrane per-
proved biocompatibility to reduced Amadori adduct for-meability [89]. Honda et al noted that AGE deposition
mation (abstract; J Am Soc Nephrol 9:278A, 1998).correlated with increasing severity of interstitial fibrosis
The lower potential of icodextrin for in vitro glycationand vascular sclerosis, raising the possibility that AGE
of proteins and for AGE formation is beginning to beaccumulation enhanced the progression of peritoneal fi-
borne out in animal studies. A significantly reduced levelbrosis and vascular changes, resulting in impaired ultra-
of peritoneal membrane AGE staining was reported infiltration capacity [52]. All of these studies suggest a
normal rats dialyzed with icodextrin versus 2.27% glu-strong causal relationship between the uremic state, du-
cose (2.5% dextrose) solution, as well as a reduction inration of dialysis, AGE-mediated membrane alterations
both membrane thickness and TGF- staining, indicatingand the decline of ultrafiltration. It is in this context that
a less fibrotic and by definition, a more biocompatiblewe now review the potential role that icodextrin may
physiology (abstract; Kim et al, J Am Soc Nephrol 10:play in GDP- and AGE-associated membrane changes.
317A, 1999). Lee et al has recently reported that diabetic
rats dialyzed with icodextrin had significantly lower peri-
GLYCATION OF PERITONEAL PROTEINS, toneal AGE staining than did rats dialyzed with glucose
AMADORI ADDUCT AND AGE FORMATION (Fig. 7) [96], underscoring the potential of icodextrin for
minimizing AGE-mediated membrane alterations.Glucose is associated with the non-enzymatic glycation
In a prospective clinical study, Posthuma et al foundof proteins in vitro [90], a process that indirectly leads
that while icodextrin reduced the formation of Amadorito the formation of Amadori adducts. AGEs have been
albumin and AGE protein in vitro, there was no differ-shown to reduce the HPMC viability in vitro in a dose-
dependent fashion [53]. The binding of glycated albumin ence in effluent levels of early (Amadori albumin) or ad-
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vanced (AGE-derived fluorescence) markers in CCPD nated, there might be an avenue for reducing in vivo
glycation and AGE formation.patients using icodextrin or glucose-based solutions for
their daytime dwells over a two year period [95]. In a
short-term study conducted by Ho-dac-Pannekeet et al, BIOCOMPATIBILITY OF ICODEXTRIN
the levels of the advanced glycation marker pentosidine
We have now reviewed the effects of icodextrin andin effluents of patients using glucose- or icodextrin-based
glucose-based solutions on cell and membrane functionsPD solutions essentially confirmed Posthuma et al’s find-
in numerous in vitro, ex vivo, and in vivo studies. Theings of no significant differences in the two patient popu-
biocompatibility of icodextrin can be addressed in twolations [97]. The authors of both studies attributed the
ways: first, in a very straightforward fashion by determin-lack of difference in glycation and/or AGE levels in the
ing how the initial biocompatibility criteria have beenicodextrin and glucose effluents to “washout” of com-
met and what the assessment seems to be; and secondly,pounds from the peritoneal tissues during the dwell, a
and just as importantly in the long run, by determiningphenomenon observed previously [54, 78].
how icodextrin fits into a much broader therapeutic strat-These studies suggest that during PD there is bi-direc-
egy of enhancing PD.tional movement of both RCOs and AGE-modified pro-
The formulation of icodextrin-based PD solution does
teins across the peritoneal membrane. There appears to
address three of the four biocompatibility factors in a
be an influx of GDPs and RCOs from the solution into manner to suggest improved biocompatibility. Of the
the tissue, and an outflow of total RCOs and AGEs from four factors, only low pH/lactate is not corrected in its
the tissues and circulation into the effluent, that is, the formulation. Since icodextrin is a long dwell solution,
“washout” referred to by these authors. The variables be- with one exchange over a 9 to 12 hour period with seem-
ing measured in these studies—effluent glycation and ingly rapid equilibration of pH upon instillation, the ef-
AGE protein levels—are more indicative of ongoing trans- fect of low pH would be minimized over the time of
membrane transport than the state of permanent mem- the exchange. Due to its formulation as an iso-osmotic
brane modification. Thus, interpretation of these results solution, the biocompatibility disadvantages with hyper-
is limited, as they would not accurately reflect membrane osmolarity are avoided. Replacing glucose with icodex-
AGE content or, more importantly, membrane struc- trin eliminates the issues of direct glucotoxicity and
tural changes associated with AGE formation. clearly reduces the GDP content.
In addition, all of the patients in these studies used We have calculated the potential reductions in both
glucose-based solutions prior to beginning the study, and peritoneal membrane glucose exposure and GDP ab-
by necessity continued to use them for their non-icodex- sorption we would achieve through the use of icodextrin
trin exchanges. Therefore, their persistent exposure to for the long dwell exchange (Fig. 8). These calculations
glucose and elevated GDPs may have overwhelmed the assume a CAPD regimen of three 2.5-L exchanges with
biocompatibility impact of the icodextrin exchange. Sec- 1.36% glucose (1.5% dextrose) and an overnight exchange
ond, the time on study was too short to see an effect, of either 7.5% icodextrin or 3.86% glucose (4.25% dex-
certainly in the Ho-dac-Pannekeet study, but probably trose). With a reduction in daily peritoneal membrane
also in the Posthuma study; the authors acknowledge glucose exposure of 48.6%, and decreases of 48%, 47%,
this in a subsequent publication on the same study [66]. and 24% in peritoneal absorption of 3-DG, glyoxal, and
AGE accumulation in the membrane occurs over time methylglyoxal, respectively (the three GDPs that appear
and the subsequent AGE-mediated changes in mem- to be most reactive in contributing to AGE formation),
brane structure and function take even longer for their the use of icodextrin should be strongly recommended
effects to become measurable. It is known that substan- for reducing the potential avenues of glucose-induced
tial changes in small solute transport and reductions in toxicity, and GDP-mediated AGE formation and perito-
ultrafiltration appear only after three to four years on neal membrane alterations.
conventional solutions [98], and we would expect that Icodextrin appears to be more biocompatible than glu-
to hold true here. cose-based solutions in that it has fewer detrimental ef-
Ho-dac-Pannekeet et al also reported that in five out fects on normal cell and membrane function as demon-
of six patients with ultrafiltration failure, a six-week regi- strated in a variety of in vitro, ex vivo, and in vivo assays.
men of non-glucose dialysis (the specifics of the solutions Several incongruous case reports of sterile peritonitis as-
were not detailed) resulted in decreased effluent pentosi- sociated with the use of icodextrin-based PD solution
dine levels; the differences approached but did not have been reported to date [99–102], the cause of which
achieve statistical significance [97]. The results of their is currently under study. Nonetheless, with over 9000 pa-
study strongly implicate ongoing glucose exposure in tients using icodextrin-based solution worldwide at the
the glycation of peritoneal proteins, and suggest that if time of this review, it appears to be a safe and well-
tolerated PD therapy.glucose and/or GDP exposure is more effectively elimi-
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Fig. 8. Potential reduction in peritoneal membrane glucose and GDP exposure with icodextrin. Peritoneal membrane exposure to glucose and
GDP absorption was based on an assumed daily regimen of three 5-hour dwells of 1.36% glucose (1.5% dextrose) and a 9-hour dwell of either 7.5%
icodextrin ( ) or 3.86% glucose ( ; 4.25% dextrose). Peritoneal glucose exposure was calculated assuming total glucose absorption for each dwell.
GDP absorption was calculated for 3-DG, methylglyoxal, and glyoxal from the addition of the AUC values for each exchange over 24 hours and the
kinetics of clearance of GDPs from Miyata et al [54]. Differences between glucose and glucose/icodextrin regimens are given as a percent decrease.
The strategy for improving the biocompatibility of PD A complete regimen would include the use of biocom-
patible solutions for all exchanges: the use of icodextrinsolutions relies on an understanding of the relationship
as the long dwell exchange, with its associated reductionbetween the patient, the solution, and the membrane. It
in glucose and GDP exposure, along with the use of lowis a complex inter-dependency with all three components
glucose or low GDP solutions in all other exchanges. Pa-influencing the biocompatibility of the dialysis therapy.
tients might undergo more rigorous monitoring for gly-Much of the focus on icodextrin’s biocompatibility has
cemic control to minimize systemic glucotoxic effects.been on the removal of glucose and subsequent reduction
There are AGE blockers, AGE cross-link breakers, andof all of the glucose-mediated events. We must not for-
RCO scavengers in pre-clinical or clinical developmentget that the uremic milieu and PD solutions are co-con-
that could be extremely valuable in preventing or revers-tributors to membrane dysfunction through both glu-
ing not only solution, but uremic RCO-mediated mem-cose-related toxicities and carbonyl/oxidative stress. It
brane alterations [88]. In addition, a well-defined systemmust be recognized and understood how each of these
of monitoring outcomes, either through clinical trials orentities contributes to compromised membrane perfor-
a biopsy registry [103], is essential. Ultimately, the valuemance before the appropriate therapeutic strategy may
of improved biocompatibility through the use of novelbe adopted.
solutions such as icodextrin will be demonstrated by the
success of the overall therapy in which the solution plays
STRATEGY TO IMPROVE an integral role.
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